Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial
Aims: Intracoronary infusion of autologous nucleated bone marrow cells (BMCs) enhanced the recovery of left ventricular ejection fraction (LVEF) after ST-segment elevation myocardial infarction (STEMI) in the randomised-controlled, open-label BOOST trial. We reassessed the therapeutic potential of n...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 April 2017
|
| In: |
European heart journal
Year: 2017, Volume: 38, Issue: 39, Pages: 2936-2943 |
| ISSN: | 1522-9645 |
| DOI: | 10.1093/eurheartj/ehx188 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/eurheartj/ehx188 Verlag, Volltext: https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/eurheartj/article/38/39/2936/3744585 
|
| Author Notes: | Kai C. Wollert, Gerd P. Meyer, Jochen Müller-Ehmsen, Carsten Tschöpe, Vernon Bonarjee, Alf Inge Larsen, Andreas E. May, Klaus Empen, Emmanuel Chorianopoulos, Ulrich Tebbe, Johannes Waltenberger, Heiko Mahrholdt, Benedikta Ritter, Jens Pirr, Dieter Fischer, Mortimer Korf-Klingebiel, Lubomir Arseniev, Hans-Gert Heuft, Jan E. Brinchmann, Diethelm Messinger, Bernd Hertenstein, Arnold Ganser, Hugo A. Katus, Stephan B. Felix, Meinrad P. Gawaz, Kenneth Dickstein, Heinz-Peter Schultheiss, Dennis Ladage, Simon Greulich, and Johann Bauersachs |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1580491251 | ||
| 003 | DE-627 | ||
| 005 | 20230427065702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180829s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehx188 |2 doi | |
| 035 | |a (DE-627)1580491251 | ||
| 035 | |a (DE-576)510491251 | ||
| 035 | |a (DE-599)BSZ510491251 | ||
| 035 | |a (OCoLC)1341017780 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wollert, Kai Christoph |d 1964- |e VerfasserIn |0 (DE-588)134248295 |0 (DE-627)564828815 |0 (DE-576)300401744 |4 aut | |
| 245 | 1 | 0 | |a Intracoronary autologous bone marrow cell transfer after myocardial infarction |b the BOOST-2 randomised placebo-controlled clinical trial |c Kai C. Wollert, Gerd P. Meyer, Jochen Müller-Ehmsen, Carsten Tschöpe, Vernon Bonarjee, Alf Inge Larsen, Andreas E. May, Klaus Empen, Emmanuel Chorianopoulos, Ulrich Tebbe, Johannes Waltenberger, Heiko Mahrholdt, Benedikta Ritter, Jens Pirr, Dieter Fischer, Mortimer Korf-Klingebiel, Lubomir Arseniev, Hans-Gert Heuft, Jan E. Brinchmann, Diethelm Messinger, Bernd Hertenstein, Arnold Ganser, Hugo A. Katus, Stephan B. Felix, Meinrad P. Gawaz, Kenneth Dickstein, Heinz-Peter Schultheiss, Dennis Ladage, Simon Greulich, and Johann Bauersachs |
| 264 | 1 | |c 19 April 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.08.2018 | ||
| 500 | |a Online publish-ahead-of-print 19 April 2017 | ||
| 520 | |a Aims: Intracoronary infusion of autologous nucleated bone marrow cells (BMCs) enhanced the recovery of left ventricular ejection fraction (LVEF) after ST-segment elevation myocardial infarction (STEMI) in the randomised-controlled, open-label BOOST trial. We reassessed the therapeutic potential of nucleated BMCs in the randomised placebo-controlled, double-blind BOOST-2 trial conducted in 10 centres in Germany and Norway. Methods and results: Using a multiple arm design, we investigated the dose–response relationship and explored whether γ-irradiation which eliminates the clonogenic potential of stem and progenitor cells has an impact on BMC efficacy. Between 9 March 2006 and 16 July 2013, 153 patients with large STEMI were randomly assigned to receive a single intracoronary infusion of placebo (control group), high-dose (hi)BMCs, low-dose (lo)BMCs, irradiated hiBMCs, or irradiated loBMCs 8.1 ± 2.6 days after percutaneous coronary intervention (PCI) in addition to guideline-recommended medical treatment. Change in LVEF from baseline (before cell infusion) to 6 months as determined by MRI was the primary endpoint. The trial is registered at Current Controlled Trials (ISRCTN17457407). Baseline LVEF was 45.0 ± 8.5% in the overall population. At 6 months, LVEF had increased by 3.3 percentage points in the control group and 4.3 percentage points in the hiBMC group. The estimated treatment effect was 1.0 percentage points (95% confidence interval, −2.6 to 4.7; P = 0.57). The treatment effect of loBMCs was 0.5 percentage points (−3.0 to 4.1; P = 0.76). Likewise, irradiated BMCs did not have significant treatment effects. BMC transfer was safe and not associated with adverse clinical events. Conclusion: The BOOST-2 trial does not support the use of nucleated BMCs in patients with STEMI and moderately reduced LVEF treated according to current standards of early PCI and drug therapy. | ||
| 700 | 1 | |a Chorianopoulos, Emmanuel |d 1974- |e VerfasserIn |0 (DE-588)122373332 |0 (DE-627)705883302 |0 (DE-576)293242550 |4 aut | |
| 700 | 1 | |a Katus, Hugo |d 1951- |e VerfasserIn |0 (DE-588)108916618 |0 (DE-627)577155040 |0 (DE-576)289625076 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d Oxford : Oxford University Press, 1980 |g 38(2017), 39, Seite 2936-2943 |h Online-Ressource |w (DE-627)320415813 |w (DE-600)2001908-7 |w (DE-576)103746846 |x 1522-9645 |7 nnas |a Intracoronary autologous bone marrow cell transfer after myocardial infarction the BOOST-2 randomised placebo-controlled clinical trial |
| 773 | 1 | 8 | |g volume:38 |g year:2017 |g number:39 |g pages:2936-2943 |g extent:8 |a Intracoronary autologous bone marrow cell transfer after myocardial infarction the BOOST-2 randomised placebo-controlled clinical trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehx188 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic-oup-com.ezproxy.medma.uni-heidelberg.de/eurheartj/article/38/39/2936/3744585 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180829 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 108916618 |a Katus, Hugo |m 108916618:Katus, Hugo |d 910000 |d 910100 |e 910000PK108916618 |e 910100PK108916618 |k 0/910000/ |k 1/910000/910100/ |p 23 | ||
| 998 | |g 122373332 |a Chorianopoulos, Emmanuel |m 122373332:Chorianopoulos, Emmanuel |d 910000 |d 910100 |e 910000PC122373332 |e 910100PC122373332 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1580491251 |e 3024107886 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Kai C. Wollert, Gerd P. Meyer, Jochen Müller-Ehmsen, Carsten Tschöpe, Vernon Bonarjee, Alf Inge Larsen, Andreas E. May, Klaus Empen, Emmanuel Chorianopoulos, Ulrich Tebbe, Johannes Waltenberger, Heiko Mahrholdt, Benedikta Ritter, Jens Pirr, Dieter Fischer, Mortimer Korf-Klingebiel, Lubomir Arseniev, Hans-Gert Heuft, Jan E. Brinchmann, Diethelm Messinger, Bernd Hertenstein, Arnold Ganser, Hugo A. Katus, Stephan B. Felix, Meinrad P. Gawaz, Kenneth Dickstein, Heinz-Peter Schultheiss, Dennis Ladage, Simon Greulich, and Johann Bauersachs"]},"language":["eng"],"person":[{"display":"Wollert, Kai Christoph","given":"Kai Christoph","family":"Wollert","role":"aut"},{"display":"Chorianopoulos, Emmanuel","given":"Emmanuel","family":"Chorianopoulos","role":"aut"},{"given":"Hugo","display":"Katus, Hugo","role":"aut","family":"Katus"}],"recId":"1580491251","note":["Gesehen am 29.08.2018","Online publish-ahead-of-print 19 April 2017"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Intracoronary autologous bone marrow cell transfer after myocardial infarction","title":"Intracoronary autologous bone marrow cell transfer after myocardial infarction","subtitle":"the BOOST-2 randomised placebo-controlled clinical trial"}],"physDesc":[{"extent":"8 S."}],"id":{"eki":["1580491251"],"doi":["10.1093/eurheartj/ehx188"]},"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Intracoronary autologous bone marrow cell transfer after myocardial infarction the BOOST-2 randomised placebo-controlled clinical trialEuropean heart journal","part":{"text":"38(2017), 39, Seite 2936-2943","issue":"39","extent":"8","pages":"2936-2943","volume":"38","year":"2017"},"language":["eng"],"note":["Gesehen am 12.09.2017"],"pubHistory":["1.1980 -"],"id":{"zdb":["2001908-7"],"issn":["1522-9645"],"eki":["320415813"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"European heart journal","title_sort":"European heart journal"}],"origin":[{"dateIssuedKey":"1980","publisherPlace":"Oxford ; London [u.a.]","publisher":"Oxford University Press ; Harcourt","dateIssuedDisp":"1980-"}],"recId":"320415813"}],"origin":[{"dateIssuedDisp":"19 April 2017","dateIssuedKey":"2017"}]} | ||
| SRT | |a WOLLERTKAIINTRACORON1920 | ||